A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology

By afschroeder • August 3, 2025

Tereshchenko LG, Manyara AM, Ciani O, Sodeke SO, Bradford CN, Santangeli P, Kapadia SR, Wazni O, Narayan SM, Chugh SS, Bilchick K, Huizar JF, Vaseghi M, Chung MK, Ellenbogen KA, Taylor RS. A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology. Heart Rhythm. 2025 Aug;22(8):e492-e499. doi: 10.1016/j.hrthm.2025.02.038. Epub 2025 Feb 26. PMID: 40021073; PMCID: PMC12317828.

Tags: Biomarker, Cardiology/Epi, Cedars Sinai DoM, Checklist, Clinical Trial, Outcome, Publications, Randomized Controlled Trial, Research design, standards, Surrogate end point, surrogate marker

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

Hoffman R, Watanabe M, Martínez E, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Lu[...]

Lipids and lipoproteins in calcific aortic valve disease

Aksoy O, Tintut Y, Demer LL. Lipids and lipoproteins in calcific aortic valve disease. Curr Opin Lipidol. 2026 Oct 1;37(5):185-190. doi: 10.1097/MOL.0000000000001053. Epub 2026 Aug[...]

Lipids in endothelial-to-mesenchymal transition

Tripsas CK, Tsai AY, Hsu JJ. Lipids in endothelial-to-mesenchymal transition. Curr Opin Lipidol. 2026 Oct 1;37(5):177-184. doi: 10.1097/MOL.0000000000001051. Epub 2026 Aug 12. PMID: 42592967.